Avid Bioservices Inc (CDMO)

[bimerkjaere]

My belief was that the pancreatic trial was too early to project any benefit. However, the 1st-line NSCLC MOS appears to have more room for a low side surprise. The trial is around 17mo post enrollment, and even a reading of 12-13 mos would be a marginal win, and enough to move to Ph 3. With mngt indicating 1H13 as expected read-out, we likely have a couple of months of cushion yet to come.

The 2nd-line results are a bit of a mystery with the censored patients and new control arm, but I think they still will warrant Ph 3 go by the FDA.

Also, IMO this was an overreaction to one trial outcome in one tumor type. Just as one can overestimate efficacy from a small ph 2, one can read too much into a negative result and project it on to the entire MOA.

What us ihubers should do is try determine if there is a difference in the tumor microenvironment between lung and pancreatic tumors that might explain the differences in bavi efficacy.